Results & investor presentations

Overview

Results, press releases & publications

Brought together here for easy access, explore all the press releases, presentations, reports, calls and webcasts DSM has published in the last decade on its financial results, Capital Markets Days and Shareholders' meetings.

You can also find an overview of all the financial and regulatory press releases disclosing price-sensitive inside information issued during the same period.

Q3 trading update

02 Nov

DSM accelerates its purpose-led, performance-driven strategic journey

14 Sep

DSM to acquire First Choice Ingredients

03 Sep

H1 2021 results

03 Aug

(Virtual) Annual General Meeting of Shareholders

06 May

Q1 trading update

05 May

Annual Report 2020

02 Mar

Annual Results 2020

16 Feb

Financial & regulatory press releases

Disclosure of price-sensitive inside information

DSM is obliged by article 17 of the European Market Abuse Regulation to disclose price-sensitive inside information to the Dutch Authority for the Financial Markets (AFM) and to publish this information via a press release. Full details of the AFM's rules on the disclosure of inside information and relevant definitions can be found on their website.

Below are the financial and regulatory press releases published during the last decade. The AFM also maintains an independent public register of these press releases.

  • DSM provides Q3 2022 trading update

    01 Nov 2022

    DSM’s trading update for the first nine months of 2022 is out now and our Health, Nutrition & Bioscience businesses all delivered good sales growth. Market demand remained resilient in what is a challenging macro-economic environment with the rising cost inflation.

  • DSM announces sale of Engineering Materials business

    31 May 2022

    Royal DSM, a global purpose-led science-based company, today announces that it has reached an agreement to sell its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion.

  • Final dividend 2021 Royal DSM

    10 May 2022

    Royal DSM, a global purpose-led science-based company, confirmed its resolution to declare a dividend for the financial year 2021 of €2.50 per ordinary share was passed today, 10 May 2022, at its Annual General Meeting of Shareholders.

  • DSM - repurchase of shares (2-6 May 2022)

    10 May 2022

    Royal DSM, a global purpose-led science-based company, has repurchased 40,085 of its own shares in the period from 2 May 2022 up to and including 6 May 2022 at an average price of €156.08.

  • DSM - repurchase of shares (25-29 April 2022)

    03 May 2022

    Royal DSM, a global purpose-led science-based company, has repurchased 157,671 of its own shares in the period from 25 April 2022 up to and including 29 April 2022 at an average price of €156.34.

  • DSM - repurchase of shares (18-22 April 2022)

    26 Apr 2022

    Royal DSM, a global purpose-led science-based company, has repurchased 142,403 of its own shares in the period from 18 April 2022 up to and including 22 April 2022 at an average price of €155.73.

  • DSM - repurchase of shares (11- 15 April 2022)

    20 Apr 2022

    Royal DSM, a global purpose-led science-based company, has repurchased 101,258 of its own shares in the period from 11 April 2022 up to and including 15 April 2022 at an average price of €158.07.

  • DSM - repurchase of shares (4- 8 April 2022)

    12 Apr 2022

    Royal DSM, a global purpose-led science-based company, has repurchased 173,491 of its own shares in the period from 4 April 2022 up to and including 8 April 2022 at an average price of €162.36.

  • DSM - repurchase of shares (28 March-1 April 2022)

    05 Apr 2022

    Royal DSM, a global purpose-led science-based company, has repurchased 171,521 of its own shares in the period from 28 March 2022 up to and including 1 April 2022 at an average price of €162.39.

  • DSM provides preliminary 2021 comparative figures

    04 Apr 2022

    Royal DSM, a global purpose-led science-based company, today provides preliminary comparative financial figures for 2021 following the establishment of DSM’s Health, Nutrition & Bioscience (“HNB”) structure, which became effective as of 1 January 2022.

  • DSM - repurchase of shares (21-25 March 2022)

    29 Mar 2022

    Royal DSM, a global purpose-led science-based company, has repurchased 205,518 of its own shares in the period from 21 March 2022 up to and including 25 March 2022 at an average price of €160.28.

  • FrieslandCampina and DSM take major step to reduce greenhouse gas emissions from dairy cattle

    24 Mar 2022

    The Bovaer® pilot collaboration between the Dutch companies FrieslandCampina, DSM, and Agrifirm marks an important step forward in increasing the sustainability of the dairy sector. Some 200 FrieslandCampina dairy farms in the Netherlands will take part in the pilot in the second half of 2022. Providing the results are positive, the use of Bovaer® will be further upscaled from 2023.

  • DSM receives landmark EU market approval for its methane-reducing feed additive Bovaer®

    24 Feb 2022

    Royal DSM, a global purpose-led science-based company, announces that European Union (EU) member states approved the marketing of the methane-reducing feed additive for dairy cows, Bovaer®, in the EU. After inclusion in the EU registry, expected in the coming weeks, it is the first time a feed additive authorised in the EU for environmental benefits can be marketed. This marks a significant milestone for DSM, paving the way for Bovaer® to revolutionize the dairy market.

  • DSM reports 2021 results

    15 Feb 2022

    Strong financial growth alongside significant progress toward our sustainability and strategy ambitions made 2021 a year to be proud of.

Read more

  • Factbooks

    Factbooks

    DSM's Factbook provides investors and analysts with an introduction to the company and our key individual businesses.